Market capitalization | HKD32.83b |
Enterprise Value | HKD34.50b |
P/E (TTM) P/E ratio | 14.03 |
EV/FCF (TTM) EV/FCF | 26.52 |
EV/Sales (TTM) EV/Sales | 2.96 |
P/S ratio (TTM) P/S ratio | 2.82 |
P/B ratio (TTM) P/B ratio | 2.09 |
Dividend yield | 2.65% |
Last dividend (FY24) | HKD0.26 |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
4 Analysts have issued a Grand Pharmaceutical forecast:
4 Analysts have issued a Grand Pharmaceutical forecast:
Dec '24 |
+/-
%
|
||
Revenue | 11,645 11,645 |
11%
11%
|
|
Gross Profit | 6,738 6,738 |
3%
3%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 2,284 2,284 |
11%
11%
|
Net Profit | 2,468 2,468 |
31%
31%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Grand Pharmaceutical Group Ltd. is an investment holding company, which engages in the development, manufacture and distribution of pharmaceutical products. The company employs 11,987 full-time employees The firm is mainly engaged in the manufacture and sale of pharmaceutical preparations and medical devices. The firm is also engaged in the manufacture and sale of biotechnology products, health products, specialised pharmaceutical raw materials and other products. The firm's main products include nuclear medicine anti-tumor diagnosis and treatment and cardiovascular and cerebrovascular interventional diagnosis and treatment technology products.
Head office | Hong Kong |
Employees | 11,987 |
Website | www.grandpharma.cn |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.